In this free webinar, learn about the complement therapeutics landscape. Attendees will gain insights into the different stages of drug development and the experiences of the panelists within these stages. The featured speakers will discuss challenges and potentials in modern therapeutics. Attendees will learn about the tools used in drug development, especially functional assays, and how these can support the development of next-generation complement therapeutics.
TORONTO, March 20, 2023 /PRNewswire-PRWeb/ -- Complement is an important and integral part of the immune system known to interact with a wide range of tissues and cells across the body. However, only recently has it become an attractive therapeutic target. In this panel discussion, attendees will gain knowledge on the challenges and potentials of complement therapeutics from drug discovery all the way through to clinical testing.
The introduction of Eculizumab, the pioneering complement modulator, demonstrated that targeting the complement system is well-tolerated, provides beneficial treatment and can change, and potentially save, lives. The rise in the number of conditions linked to dysregulation of the complement system clearly underscores the potential of complement-modulating therapeutics.
However, many attempts to make new drugs have failed. This has served as a valuable lesson to scientists and researchers, highlighting the importance of understanding the complexities of the complement system and the need for specialized tools to successfully develop effective drugs.
Over the last few decades, multiple initiatives have been launched — because of both the success with Eculizumab and a better understanding of the complement system — ranging from academic laboratories to large pharmaceutical companies exploring further the potential of regulating the complement system. A considerable number of these complement therapeutics have entered clinical development, and several are even in advanced late trial stages.
Equipped with these insights and the technical advancements in biological drug design, novel complement modulating drugs are emerging to avoid previous pitfalls and thus increase the chances of clinical success. This creates a promising outlook for those aiming to leverage the potential therapeutic applications of modulating the complement system and bringing it to the clinic to improve the health of patients.
Register for this webinar to hear from experts on next-generation complement therapeutics as they provide perspectives and insights from each stage of the drug development process.
Join Dr. Michael Schwenkert, Chief Technology Officer, Svar Life Science; Dr. Christoph Schmidt, Professor of Biochemical Pharmacy, Institute of Pharmacy, Martin-Luther University of Halle-Wittenberg; Dr. Előd Körtvély, Principal Scientist, Pharma Research and Early Development (pRED), Roche Innovation Center; Dr. Sandra Wymann, Senior Manager, Translational Research, CSL Behring AG, for the live webinar on Tuesday, April 11, 2023, at 11am EDT (4pm BST/UK).
For more information, or to register for this event, visit Next-Generation Complement Therapeutics — Exploring Challenges and Solutions from Bench to Bedside.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: [email protected]
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected]
SOURCE Xtalks
Share this article